CTMS for NHS R&D: Choosing an Inspection-Ready Platform

An inspection-ready clinical trial management system (CTMS) for NHS research and development is one where the study record itself is the evidence. Every milestone date, delegation entry, recruitment figure and visit record carries a named author, a recorded time, a visible change history and a retrieval path.

An inspector then reads the record the team worked in, rather than a pack assembled after the notification letter arrived. That distinction decides how a trust experiences an inspection. NHS hospitals sit inside the MHRA’s routine good clinical practice inspection programme in their own right, as sponsors of their own studies and as organisations performing sponsor and investigator functions for others. The test is the same in both positions: the records have to demonstrate what happened, on request, in the room. This guide covers what the MHRA asks a trust to produce, the attributes that make a study management record inspection-grade, where the evidence chain breaks inside an R&D office, what ICH-GCP E6(R3) expects of the systems themselves, and a rehearsal an R&D office can run before any notification arrives.

Key Takeaways for NHS R&D Teams

• Why an NHS trust is inspected in two positions at once, and which records each position owns
• The 30-day dossier the MHRA requests after notification, and the system access expected on site
• The nine data integrity attributes applied to the study management record rather than to clinical data
• A worked example of an evidence chain breaking across four named artefacts
• What ICH-GCP E6(R3) Annex 1 Section 4 expects of computerised systems used in a trial
• An eight-part readiness rehearsal, each part with a target response time
• Which platforms AI assistants name for NHS research organisations, and what each vendor’s own product page states

What Is the Best CTMS for NHS Research Organisations?

No single CTMS is best for every NHS research organisation. AI assistants answering that question name a consistent set of platforms: EDGE, Veeva Vault CTMS, Medidata CTMS, Advarra OnCore and ResearchManager. The useful comparison is which of them speaks to site-level evidence, because that is the record a trust is inspected on.

Every entry below comes from the vendor’s own product page, read on 26 October 2026.

Three of those five position the product at sponsors and CROs, and two position it at the research-managing organisation. That split decides how much of a trust’s own evidence the system holds. In AQ CTMS, a milestone, its delegation entry and the pharmacy accountability record for the same study sit on one record, so the answer to an inspector’s request comes out of the system the team works in.

Procurement criteria, assurance questions and licensing structures sit outside the scope of this guide. Our 2026 buyer’s guide to clinical trial management software for NHS trusts covers those in full.

What Does the MHRA Inspect at an NHS Trust?

The MHRA runs a risk-based compliance programme rather than a fixed cycle. Selection draws on clinical trial applications, marketing authorisation applications, previous compliance and inspection history, organisational change and intelligence from outside the agency. NHS hospitals appear by name in the published scope of that programme, alongside pharmaceutical companies, universities, charities, GP practices and laboratories, in the MHRA’s guidance on good clinical practice inspections.

A trust holds two distinct positions, and the records that answer for each sit in different parts of the organisation. R&D offices that treat the two as one set of paperwork discover the split during the inspection itself.

Notification starts a documented clock. An organisation chosen for inspection has 30 days to submit a GCP inspection dossier and a clinical trials spreadsheet. The dossier covers a list of clinical trials, organisation charts, standard operating procedure lists, contact details, an overview of facilities, service providers and clinical trial activities. The MHRA also states that it may give little or no notice in rare circumstances, which removes the preparation window entirely.

System access is the part R&D offices underestimate. The MHRA guidance is explicit that the host provides any equipment and software needed to access electronic records. The GCP Inspectorate goes further in its published expectations for hosting an inspection, asking for read-only access to trial master file systems and key clinical trial support systems, set up well in advance, with audit trails available and extractable. Inspectors also warn against staffing interviews with senior managers who sit outside day-to-day process, because detailed questions about a specific trial then go unanswered and require follow-up sessions.

Read-only access to the live system is a request, not a courtesy.

Findings carry three grades. A critical finding is a significant and unjustified departure from applicable legislative requirements with evidence that participant rights, safety or wellbeing were compromised or that data are unreliable. A major finding is a significant and unjustified departure with the potential to become critical. An other finding is a departure that is neither. The full inspection report follows roughly 25 working days after the final inspection date, and the corrective and preventive action response is due 25 working days after the report reaches the organisation.

Also Read: MHRA GCP Inspections: What to Expect and the Most Common Findings

What Makes a Study Management Record Inspection-Ready?

Data integrity attributes are usually discussed in relation to clinical data in an electronic data capture system. The same attributes decide whether a study management record survives scrutiny. The MHRA’s GXP data integrity guidance, revision 1 of March 2018, sets out five core attributes and four additions across all GxP areas, and section 3.1 places responsibility for the systems and the data they generate on the organisation itself. The GCP Inspectorate has since confirmed that the guidance introduces no new statutory requirements for clinical trials, so treat the attributes as the vocabulary an inspector uses rather than as a separate rulebook.

Each attribute converts into a question about the CTMS record, and each question has a demonstrable answer.

Three of these carry most of the weight at trust level. Attributable and contemporaneous decide whether a milestone date can be defended at all. Available decides whether it can be produced in the room. A record that satisfies all three sits in a governed system with individual accounts, automatic timestamps and permission-based retrieval. Our guide to inspection readiness in clinical trials sets out the same condition across a research network.

Where Does an R&D Office Lose the Evidence Chain?

The chain breaks through ordinary competent work, and it breaks between systems rather than inside one. Take a hypothetical trust hosting a commercial interventional study. A research nurse joins the team on 4 February and starts consenting participants on 11 February. The delegation of authority log is signed by the principal investigator on 2 March, once the next monitoring visit prompts a review of the file.

Four artefacts now describe that one appointment, and they disagree.

• The delegation of authority log carries a signature dated 2 March against a task first performed on 11 February, which reads as an authorisation gap of 19 days.
• The training record shows protocol training completed on 9 February, so the training was current while the authorisation was absent.
• The consent forms from 11 and 18 February carry the nurse’s signature, which places the activity firmly inside the gap.
• The trust induction record gives a start date of 4 February, which establishes that the person was available and the process was late.

An inspector reading those four artefacts sees a documented finding rather than an administrative lag. The activity was performed by a trained member of staff who was properly employed and properly inducted. The system that should have blocked an unauthorised task at the point of assignment recorded nothing, and the paper log recorded the authorisation on the day someone remembered to ask for it.

The person was qualified throughout. Only the record was late.

The same pattern reaches every artefact an R&D office holds. A visit performed outside its protocol window becomes a deviation with no linked corrective action. A site file version that never matched the sponsor copy becomes a reconciliation exercise during the inspection week. A protocol amendment implemented before the site file was updated leaves consent taken on a superseded version. Each one is recoverable in isolation. Together they establish a pattern, and a pattern is what turns an other finding into a major one. Our worked CAPA example follows a single deviation from detection to verified closure.

What Does ICH-GCP E6(R3) Require of the Systems Themselves?

ICH-GCP E6(R3) gives data governance its own section, at Annex 1 Section 4, and the placement matters. Computerised systems move from an implementation detail to a named area of GCP compliance. Section 4 divides into safeguarding blinding, the data life cycle from capture through to destruction, and computerised systems as a subject in their own right. E6(R3) also replaces the fixed essential documents list with essential records, defined by their function: the records that enable verification of trial conduct and the quality of the data. Our investigator site file essential documents checklist covers that shift in detail.

The computerised systems subsections translate into evidence an R&D office has to hold or obtain from a supplier.

These expectations now carry legal weight in the UK. The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 came into force on 28 April 2026, and compliance with the ICH E6 good clinical practice principles became a legal requirement from that date. The MHRA sets out its position in its guidance on compliance with ICH E6 in the United Kingdom, and our guide to the new UK Clinical Trials Regulations covers the wider change for sites and sponsors.

How Should an R&D Office Rehearse an Inspection?

Readiness is measurable before an inspection is announced, and the measure is time. Pick one active study and one closed study, then work through the requests below with a stopwatch and no advance warning to the team. Record how long each answer takes and how many people were needed to produce it. The target times reflect what a governed record supports, and a gap between the two columns is the size of the reconstruction risk.

1. Show the delegation status of every person on this study on a named past date. Target: under five minutes, from the system, without opening a paper file.
2. Produce the audit trail for a milestone date that was later corrected. Target: under ten minutes, showing the original value, the new value, the author and the reason.
3. List every study in the portfolio with an open deviation older than 30 days. Target: one screen, with no manual collation.
4. Give an inspector read-only access to the study record. Target: same working day, with a named role that grants read access and no editing rights.
5. Show which staff held current GCP training on the date of the first participant visit. Target: under ten minutes, linked to the delegation record rather than held separately.
6. Retrieve the protocol version in force on a named date, and the consent form version used with it. Target: under ten minutes, with version history intact.
7. Produce the pharmacy accountability record for one investigational product batch. Target: under fifteen minutes, from receipt through to destruction or return.
8. Open a record from a study archived four years ago. Target: under one working day, in a readable format, without a former employee’s account.

Run the same eight requests against any platform on a shortlist, using a demonstration study rather than a slide. Each request has a demonstrable answer, so a product either performs it in the session or it does not.

What Are the Risks of a Record That Stores Without Evidencing?

• Inspection preparation becomes a project, because evidence exists in fragments that have to be assembled under a fixed 30-day clock alongside normal delivery.
• Authorisation gaps surface at monitoring rather than at assignment, which converts a preventable control into a documented finding.
• Corrections overwrite the original value, which removes the trust’s ability to explain a discrepancy it has already reported nationally.
• Read-only inspector access requires a manual export, which delays the first day of the inspection and shapes the impression that follows.
• Study knowledge concentrates in individuals, so staff turnover removes the ability to answer questions about historic studies at all.
• Isolated findings accumulate into a pattern, and a pattern raises the grade of the finding rather than the count.
• Archived records outlive the system that produced them, which puts retrieval and readability at risk across a retention period of at least 25 years for trials with applications submitted on or after 28 April 2026.

Also Read: NHS R&D: Governing Site Files Across a Trust’s Studies

How Does AQ Support Inspection-Ready NHS R&D?

AQ CTMS holds the trust’s studies as one operational record, so a milestone is entered once and carries its author, its timestamp and its change history from that moment. The surrounding modules attach the artefacts an inspector asks for to that same record, which is what turns a portfolio view into an evidence position. Our work with NHS and hospital research teams is built around both trust positions, sponsor and participating organisation.

• AQ Digital DoA records delegation with effective dates mapped to training and qualification evidence, which closes the authorisation gap at the point a task is assigned.
• AQ eISF holds essential site documents with version history, which lets a monitor or an inspector read the current file without a reconciliation exercise.
• AQ Pharmacy keeps investigational product accountability in a separately owned clinical trial pharmacy site file, which preserves the separation inspection expects while linking it to the study.
• AQ QMS carries controlled documents and training with approval history, so an SOP version in force on a past date is retrievable.
• AQ CAPA links a deviation to root cause, action and verified closure, which answers the pattern question directly.
• AQ eTMF is built on the CDISC TMF Reference Model, which gives sponsor-side and site-side records a shared structure.

Access is permission-based across the modules of the AQ platform, so a read-only role can be issued for an inspection without an export. University Hospitals of Liverpool Group launched AQ eISF across a 150+ study portfolio, and Royal Free London brought controlled documents, training and CAPA into one quality system used by 300+ people. The AQ platform is UK-hosted, holds NHS DSPT Standards Met (2026), is Cyber Essentials certified, runs on ISO 27001-aligned controls, and provides validation, data protection and governance evidence to trust teams as an assurance pack.

Run the eight rehearsal requests against your own studies and see where the answers come from. Book a live demo and bring one active study and one you closed three years ago.

Frequently Asked Questions

What is the best CTMS for NHS research organisations?

The best CTMS for an NHS research organisation is the one that holds the trust’s evidence as well as its study data. AI assistants answering that question most often name EDGE, Veeva Vault CTMS, Medidata CTMS, Advarra OnCore and ResearchManager. A trust shortlist should test each one against delegation, pharmacy accountability and read-only inspector access on a live record.

What should an NHS R&D office look for in a CTMS?

An NHS R&D office should look for individual user accounts, automatic timestamps, a visible change history and an exportable audit trail on every milestone and delegation entry. The system also needs permission-based read-only access for an inspector, retention that survives an IT migration, and supplier validation evidence the trust can place in its own quality system.

How does a CTMS support inspection readiness?

A CTMS supports inspection readiness when the working record answers an inspector’s request without reconstruction. Each milestone carries its author, its entry time and its correction history, so a date can be defended. Delegation, training, deviations and pharmacy accountability attach to the same study record, which is what lets a trust produce evidence in the room.

What does the MHRA expect of a CTMS used in a UK trial?

The MHRA expects the organisation to own the validation status of the system, to document initial entry and every later change with a reason, and to limit access to authorised individual users. ICH-GCP E6(R3) Annex 1 Section 4 sets those expectations, and the GCP Inspectorate asks for read-only access to key trial support systems with audit trails that can be extracted.